Form 4: Apogee Therapeutics Insider Trades Common Stock

Carl Dambkowski, Chief Medical Officer at Apogee Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, including trades executed under a Rule 10b5-1 plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., engaged in several transactions involving the company's common stock.
• On July 1, 2026, Dambkowski acquired 4,125 shares of common stock at a price of $22.86 per share.
• On the same date, Dambkowski disposed of 5,500 shares of common stock at a price of $132.74 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Following these transactions, Dambkowski beneficially owns 177,873 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves significant share disposition by an executive, it is conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns about opportunistic insider selling.

Positives

• Acquisition of 4,125 shares of common stock at a price significantly lower than the disposition price, potentially indicating a favorable entry point for a portion of his holdings.
• The use of a Rule 10b5-1 plan suggests a pre-determined strategy for trading, which can be viewed positively for its adherence to structured financial planning.

Negatives

• Disposition of 5,500 shares of common stock at a price significantly higher than the acquisition price, indicating a substantial sale of holdings.
• The significant difference between the acquisition price ($22.86) and the disposition price ($132.74) for different tranches of shares suggests a large profit-taking event.

Risks

• The disposition of a significant number of shares by a key executive could be interpreted by the market as a lack of confidence in future stock performance, although executed under a pre-planned trading strategy.
• The Rule 10b5-1 plan, while providing an affirmative defense against insider trading allegations, still involves the sale of company stock by management.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance. However, the stock option grant indicates a long-term incentive for the reporting person, with vesting extending through December 18, 2027.

Management Comments

• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• The option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of Rule 10b5-1 plans is common practice for executives to manage their stock holdings in a structured and compliant manner, especially when significant price movements occur.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive as a signal, though the Rule 10b5-1 plan provides context that it is part of a pre-planned strategy.
• Employees: The stock option grant and vesting schedule serve as an incentive for continued service and alignment with company performance.
• Management: The transactions reflect the executive's personal financial planning and diversification strategies.

Next Steps

• Continued monitoring of Carl Dambkowski's beneficial ownership and any future transactions.
• Observation of Apogee Therapeutics' stock performance and any market reactions to insider trading disclosures.

Key Dates

Keywords

Form 4, Insider Trading, Apogee Therapeutics, Carl Dambkowski, Common Stock, Rule 10b5-1, Beneficial Ownership, Stock Option, SEC Filing